Z Prime Therapeutics
Z Prime Therapeutics is a stealth-stage precision oncology company developing a new class of therapeutics that target the specific metabolic and molecular dependencies of cancer cells. The company leverages deep biological insights to identify exploitable vulnerabilities in tumors, aiming to create treatments that selectively attack cancer cells while sparing healthy tissue and potentially overcoming resistance to existing therapies.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Cancer cells often develop resistance to existing therapies, and many tumors harbor specific metabolic or molecular dependencies that are not addressed by current treatment approaches. Identifying and therapeutically targeting these vulnerabilities remains a significant challenge in oncology, limiting treatment efficacy and patient outcomes.
Solution
Z Prime Therapeutics is pioneering a new class of precision oncology therapeutics by targeting the specific dependencies of cancer cells. The company leverages deep biological insights to identify exploitable weaknesses in tumors, designing therapies that selectively attack cancer cells while sparing healthy tissue. By focusing on the underlying molecular mechanisms that cancer cells rely on for survival and growth, Z Prime aims to develop treatments that are more effective and potentially overcome resistance. The company is currently in stealth mode, developing its proprietary platform and advancing its therapeutic candidates toward clinical evaluation.
Target Audience
Primary stakeholders are oncology researchers, biopharmaceutical partners, and investors interested in advancing next-generation precision cancer therapies.
Features
- Precision oncology platform designed to identify and target cancer cell dependencies
- Therapeutic approach aimed at exploiting hidden vulnerabilities unique to tumor biology
- Focus on developing a new class of cancer therapeutics beyond conventional treatment modalities
- Currently in stealth phase with proprietary research and development pipeline